• Cyclic Pifithrin-α Hydrobromide: p53 Inhibition for Multimod

  2026-05-16

  Explore how Cyclic Pifithrin-α hydrobromide, a powerful p53 inhibitor, enables precise modulation of the DNA damage response for apoptosis inhibition in cancer research and radioprotection. This article uniquely bridges mechanistic insights with practical assay design and highlights gaps in current neuroinflammation research.

• Vancomycin: Glycopeptide Antibiotic Benchmarks & Research Us

  2026-05-15

  Vancomycin is a high-purity glycopeptide antibiotic targeting bacterial cell wall synthesis, making it indispensable for MRSA and Clostridium difficile infection research. Its precise mechanism, solubility profile, and stringent purity standards position it as a gold-standard antibacterial agent in resistance mechanism studies.

• Lactate-Driven HMGB1 Modification and Release in Sepsis Macr

  2026-05-15

  This study reveals that lactate not only correlates with but actively promotes the release of HMGB1 from macrophages during polymicrobial sepsis via lactylation and acetylation, leading to increased endothelial permeability. The findings highlight lactate signaling as a mechanistic driver of inflammation and suggest new intervention points for sepsis research.

• Norovirus Hijacks NINJ1 for Selective Viral Protein Secretio

  2026-05-14

  Song et al. (2025) reveal that murine norovirus leverages the host cell death effector NINJ1 to selectively secrete its NS1 protein through an unconventional pathway. This discovery sheds light on how viruses manipulate regulated cell death machinery for targeted protein release, opening new avenues in both virology and cell death research.

• Capsazepine as a Novel MCL1 Inhibitor to Overcome Tamoxifen

  2026-05-14

  This study identifies capsazepine as a direct inhibitor of MCL1, demonstrating its ability to reverse tamoxifen resistance in estrogen receptor-positive breast cancer. Using a combination of virtual screening, binding assays, and functional experiments, the work highlights a promising strategy to address a persistent challenge in endocrine therapy.

• Bedaquiline Beyond the Bench: Bridging TB and Cancer Researc

  2026-05-13

  This thought-leadership article unpacks the dual-action mechanism of bedaquiline—a diarylquinoline antibiotic—highlighting its transformative role in tackling multi-drug resistant tuberculosis and targeting cancer stem cell metabolism. Drawing from recent mechanistic studies and the latest in host-directed therapy concepts, we provide translational researchers with strategic, evidence-labeled guidance for experimental design and future innovation. The article contextualizes APExBIO's bedaquiline product within the evolving competitive landscape, referencing pivotal literature and internal content assets to build a forward-looking roadmap for next-generation research.

• Hydrazide-Based VEGFR-2 Inhibitors: Antiangiogenic Advances

  2026-05-13

  This study reports the design and evaluation of 53 hydrazide-based VEGFR-2 inhibitors with strong antiangiogenic and antiproliferative properties. The lead compound, SA7, demonstrates potent VEGFR-2 inhibition and cytotoxicity, with efficacy comparable to sorafenib, highlighting its promise for future cancer biology research.

• Gamithromycin PK/PD Optimization for Pasteurella multocida i

  2026-05-12

  This study precisely characterizes the pharmacokinetics and pharmacodynamics of Gamithromycin in a murine lung infection model of Pasteurella multocida. By establishing the AUC24h/MIC ratio as the key efficacy driver, the research informs rational dosage strategies for veterinary use and translational respiratory infection models.

• DeferoxamineB in Precision Iron Modulation: Beyond Cancer Ce

  2026-05-12

  Explore how Deferoxamine (DeferoxamineB) enables precision iron modulation and advanced antioxidant strategies for cancer research. This article offers a mechanistic analysis distinct from existing content, with actionable guidance for regulated cell death assays.

• PD98059 and the Future of MEK Inhibition in Translational Re

  2026-05-11

  This thought-leadership article dissects how PD98059, a selective and reversible MEK inhibitor, provides a strategic and mechanistic foundation for next-generation translational research in oncology and neuroprotection. Drawing on recent mechanistic findings, validated protocols, and competitive insights, it empowers researchers to design experiments that bridge fundamental biology with clinically relevant outcomes.

• ABT-263 (Navitoclax) in Translational Oncology: Mechanisms a

  2026-05-11

  Explore the mechanistic and translational frontiers of ABT-263 (Navitoclax)—a potent Bcl-2 family inhibitor—through the lens of apoptosis, senescence bypass, and metabolic adaptation. This thought-leadership article provides actionable insight for translational researchers, synthesizing evidence from foundational studies and expert workflow recommendations to optimize the deployment of Navitoclax in advanced cancer biology assays and pediatric leukemia models.

• Captopril: ACE Inhibitor Benchmarks and Research Application

  2026-05-10

  Captopril is a potent ACE inhibitor with an IC50 of 6 nM, widely used in hypertension and cancer research. This article details its mechanism, protocol parameters, and evidence for both cardiovascular and oncological applications.

• MEK1/2 and c-Myc-Max Cooperate to Regulate TERT in hESCs

  2026-05-09

  This study reveals that MEK1/2 kinases and the c-Myc-Max complex jointly prevent polycomb-mediated repression of TERT in human pluripotent stem cells. The findings clarify how MAPK signaling and c-Myc transcription factor inhibition converge on telomerase regulation, with implications for stem cell biology and targeted epigenetic manipulation.

• Azilsartan Medoxomil in Hypertension: Binding, Efficacy, and

  2026-05-09

  This review analyzes the unique pharmacological properties and clinical performance of Azilsartan medoxomil (TAK 491), focusing on its high-affinity, sustained AT1 receptor antagonism in the context of essential hypertension treatment. The findings support its superior blood pressure reduction compared to other ARBs, while highlighting areas needing further investigation regarding long-term cardiovascular outcomes.

• LG 101506: RXR Modulator Driving Precision in RXR Pathway Re

  2026-05-08

  LG 101506 (RXR modulator) empowers researchers to dissect RXR-driven gene regulation and immunometabolic pathways with high purity and reproducibility. Its unique solubility and stability profile, supplied by APExBIO, enables robust experimental workflows in cell signaling, immune checkpoint biology, and metabolism regulation.

452 records 18/31 page Previous Next First page 上5页 1617181920 下5页 Last page